This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

Study Design COMPETE

Official Title

A prospective, randomized, Controlled, Open-label, Multicenter phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs).

Key Facts

COMPETE is an international, prospective (new data to be collected), randomized (patients randomly assigned by a computerized system to investigational or standard therapy group), controlled (investigational group compared to control group), open-label (patients and trial doctors know which drug is administered), multicenter phase III trial to evaluate the efficacy and safety of targeted radiopharmaceutical therapy (RPT) with n.c.a. Lutetium 177 edotreotide compared to everolimus in patients with Grade 1 or Grade 2 somatostatin receptor-positive (SSTR+) neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs).

Investigational medicinal treatment:

Targeted Radiopharmaceutical Therapy (RPT) with n.c.a. Lutetium 177 edotreotide

N.c.a. Lutetium 177 edotreotide consists of the highly pure medical radioisotope, no-carrier-added (n.c.a.) Lutetium-177 used to destroy the tumor cells by emitting a small amount of radiation, and the targeting molecule edotreotide, a synthetic form of the peptide hormone somatostatin that targets neuroendocrine tumor-specific receptors and places the medical radioisotope directly onto the diseased neuroendocrine cells. The highly precise localization can result in the healthy tissue surrounding the targeted tumor being minimally affected.

Active comparator treatment:

Everolimus, an immunosuppressive cancer therapy, established as one of the current standard of care treatments for GEP-NETs.
 

Study objectives:

Evaluate the efficacy and safety of RPT with n.c.a. Lutetium 177 edotreotide compared to everolimus in patients with Grade 1 or Grade 2 GEP-NETs.

Key Participation Features

  • special kidney protection will be provided during RPT
  • trial treatment costs will be covered
  • should travel be necessary expenses will be covered*

*based on travel distance & country and according to sponsorship regulations

The trial has been evaluated favorably by the responsible ethics committee and has been approved by the responsible authority.